Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancerJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-05-2722OAAI
未登录.png){kind=icon}
未登录
